Catherine Tsai1, Beiqun Zhao1, Theresa Chan1, Sarah L Blair2. 1. University of California, Department of General Surgery, San Diego, United States. 2. University of California, Department of General Surgery, San Diego, United States. Electronic address: slblair@ucsd.edu.
Abstract
BACKGROUND: Controversy exists regarding optimal treatment of occult breast cancer (OBC). Treatment options include mastectomy alone (MAST), radiation alone (XRT), or mastectomy with radiation (MXRT). METHODS: We queried the National Cancer Database from 2004 to 2014 for patients with OBC who underwent MAST, XRT, or MXRT. We utilized propensity score matching to perform three head-to-head comparisons. Kaplan-Meier analysis was performed to compare overall survival (OS). RESULTS: A total of 190 patients received XRT, 237 received MAST, and 244 received MXRT. In the MXRT vs. XRT comparison, 5-year OS was 78.2% and 82.8%, respectively. In the MXRT vs. MAST comparison, 5-year OS was 81.5% and 86.7%, respectively. In the MAST vs. XRT comparison, 5-year OS was 83.2% and 82.5%, respectively. There was no difference in OS for all paired comparisons. CONCLUSIONS: There were no OS differences in patients undergoing MAST, XRT, or MXRT, suggesting that breast conservation can be considered in patients with OBC. Published by Elsevier Inc.
BACKGROUND: Controversy exists regarding optimal treatment of occult breast cancer (OBC). Treatment options include mastectomy alone (MAST), radiation alone (XRT), or mastectomy with radiation (MXRT). METHODS: We queried the National Cancer Database from 2004 to 2014 for patients with OBC who underwent MAST, XRT, or MXRT. We utilized propensity score matching to perform three head-to-head comparisons. Kaplan-Meier analysis was performed to compare overall survival (OS). RESULTS: A total of 190 patients received XRT, 237 received MAST, and 244 received MXRT. In the MXRT vs. XRT comparison, 5-year OS was 78.2% and 82.8%, respectively. In the MXRT vs. MAST comparison, 5-year OS was 81.5% and 86.7%, respectively. In the MAST vs. XRT comparison, 5-year OS was 83.2% and 82.5%, respectively. There was no difference in OS for all paired comparisons. CONCLUSIONS: There were no OS differences in patients undergoing MAST, XRT, or MXRT, suggesting that breast conservation can be considered in patients with OBC. Published by Elsevier Inc.
Authors: G Vlastos; M E Jean; A N Mirza; N Q Mirza; H M Kuerer; F C Ames; K K Hunt; M I Ross; T A Buchholz; A U Buzdar; S E Singletary Journal: Ann Surg Oncol Date: 2001-06 Impact factor: 5.344
Authors: Mahmoud B El-Tamer; B Marie Ward; Tracy Schifftner; Leigh Neumayer; Shukri Khuri; William Henderson Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Natasha M Rueth; Dalliah M Black; Angela R Limmer; Emmanuel Gabriel; Lei Huo; Bruno D Fornage; Basak E Dogan; Mariana Chavez-MacGregor; Min Yi; Kelly K Hunt; Eric A Strom Journal: Ann Surg Oncol Date: 2014-09-24 Impact factor: 5.344
Authors: Lindsay K Hessler; Jason K Molitoris; Paula Y Rosenblatt; Emily C Bellavance; Elizabeth M Nichols; Katherine H R Tkaczuk; Steven J Feigenberg; Soren M Bentzen; Susan B Kesmodel Journal: Ann Surg Oncol Date: 2017-08-01 Impact factor: 5.344